Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Hammel

Showing results (161-170 of 241) with videos related to

Pageof 25
Sort By:
The Journal of Clinical Endocrinology and Metabolism|February 20, 2015
Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutationsBence Sipos, Jan Sperveslage, Martin Anlauf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patientsDaniela Speisky, Aurélie Duces, Ivan Bièche, et al.
Clinical Colorectal Cancer|October 26, 2019
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter StudyMarie Auvray, David Tougeron, Edouard Auclin, et al.
JAMA|May 4, 2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical TrialPascal Hammel, Florence Huguet, Jean-Luc van Laethem, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Cancer Treatment Reviews|June 4, 2025
Medical management of pancreatic cancer: from personalization to broadening treatment strategiesNelson Dusetti, Jean Baptiste Bachet, Brice Chanez, et al.
Histopathology|March 27, 2015
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosisCindy Neuzillet, Anne Couvelard, Annemilaï Tijeras-Raballand, et al.
Therapeutic Advances in Medical Oncology|April 3, 2023
Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimensThomas Chaigneau, Lina Aguilera Munoz, Caroline Oger, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018Deepak B Vangala, Estelle Cauchin, Judith Balmaña, et al.
Neuroendocrinology|September 4, 2015
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine TumorsJerome Cros, Emilie Moati, Jerome Raffenne, et al.
Pageof 25

Showing results (161-170 of 241) with videos related to

Sort By:
Pageof 25
The Journal of Clinical Endocrinology and Metabolism|February 20, 2015
Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutationsBence Sipos, Jan Sperveslage, Martin Anlauf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2012
Molecular profiling of pancreatic neuroendocrine tumors in sporadic and Von Hippel-Lindau patientsDaniela Speisky, Aurélie Duces, Ivan Bièche, et al.
Clinical Colorectal Cancer|October 26, 2019
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter StudyMarie Auvray, David Tougeron, Edouard Auclin, et al.
JAMA|May 4, 2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical TrialPascal Hammel, Florence Huguet, Jean-Luc van Laethem, et al.
International Journal of Cancer|May 15, 2018
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerEric Van Cutsem, Manuel Hidalgo, Jean-Luc Canon, et al.
Cancer Treatment Reviews|June 4, 2025
Medical management of pancreatic cancer: from personalization to broadening treatment strategiesNelson Dusetti, Jean Baptiste Bachet, Brice Chanez, et al.
Histopathology|March 27, 2015
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosisCindy Neuzillet, Anne Couvelard, Annemilaï Tijeras-Raballand, et al.
Therapeutic Advances in Medical Oncology|April 3, 2023
Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimensThomas Chaigneau, Lina Aguilera Munoz, Caroline Oger, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2018
Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO) expert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018Deepak B Vangala, Estelle Cauchin, Judith Balmaña, et al.
Neuroendocrinology|September 4, 2015
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine TumorsJerome Cros, Emilie Moati, Jerome Raffenne, et al.
Pageof 25